Page last updated: 2024-11-12

e 7107

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

E 7107: has antineoplastic activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16202132
CHEMBL ID4297278
SCHEMBL ID3624011
MeSH IDM0556711

Synonyms (18)

Synonym
(3r,6r,7s,8e,10s,11s,12e,14e,16r,18r,19r,20r,21s)-7-[(4-cycloheptylpiperazin-1-yl)carbonyl]oxy-3,6,16,21-tetrahydroxy-6,10,12,16,20-pentamethyl-18,19-epoyxtrichosa-8,12,14-trien-11-olide
SCHEMBL3624011
cid16202132
bdbm36359
e7107
1-piperazinecarboxylic acid, 4-cycloheptyl-, (2s,3s,4e,6s,7r,10r)-7,10-dihydroxy-2-((1e,3e,5r)-5-hydroxy-6-((2r,3r)-3-((1r,2s)-2-hydroxy-1-methylbutyl)oxiranyl)-1,5-dimethyl-1,3-hexadienyl)-3,7-dimethyl-12-oxooxacyclododec-4-en-6-yl ester
unii-r60dzx1e2n
r60dzx1e2n ,
e 7107
630100-90-2
1-piperazinecarboxylic acid, 4-cycloheptyl-, (2s,3s,4e,6s,7r,10r)-7,10-dihydroxy-2-((1e,3e,5r)-5-hydroxy-6-((2r,3r)-3-((1r,2s)-2-hydroxy-1-methylbutyl)-2-oxiranyl)-1,5-dimethyl-1,3-hexadien-1-yl)-3,7-dimethyl-12-oxooxacyclododec-4-en-6-yl ester
DB12508
[(2~{s},3~{s},4~{e},6~{s},7~{r},10~{r})-3,7-dimethyl-2-[(2~{e},4~{e},6~{r})-6-methyl-6-oxidanyl-7-[(2~{r},3~{r})-3-[(2~{r},3~{s})-3-oxidanylpentan-2-yl]oxiran-2-yl]hepta-2,4-dien-2-yl]-7,10-bis(oxidanyl)-12-oxidanylidene-1-oxacyclododec-4-en-6-yl] 4-cyclo
Q27287836
[(2s,3s,4e,6s,7r,10r)-7,10-dihydroxy-2-[(2e,4e,6r)-6-hydroxy-7-[(2r,3r)-3-[(2r,3s)-3-hydroxypentan-2-yl]oxiran-2-yl]-6-methylhepta-2,4-dien-2-yl]-3,7-dimethyl-12-oxo-1-oxacyclododec-4-en-6-yl] 4-cycloheptylpiperazine-1-carboxylate
CHEMBL4297278
EX-A6354
AKOS040745764

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacodynamic analysis revealed dose-dependent reversible inhibition of pre-mRNA processing of target genes, confirming proof-of-principle activity of E7107."( Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.
Baselga, J; Burger, H; Carreras, MJ; de Jonge, MJ; Eskens, FA; Mizui, Y; O'Brien, JP; Piera, A; Ramos, FJ; Tabernero, J; Wiemer, EA, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Splicing factor 3B subunit 3Homo sapiens (human)EC50 (µMol)0.00340.00320.00340.0036AID1799384; AID1799385
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
RNA splicing, via transesterification reactionsSplicing factor 3B subunit 3Homo sapiens (human)
mRNA splicing, via spliceosomeSplicing factor 3B subunit 3Homo sapiens (human)
regulation of DNA repairSplicing factor 3B subunit 3Homo sapiens (human)
RNA splicingSplicing factor 3B subunit 3Homo sapiens (human)
negative regulation of protein catabolic processSplicing factor 3B subunit 3Homo sapiens (human)
regulation of RNA splicingSplicing factor 3B subunit 3Homo sapiens (human)
positive regulation of DNA-templated transcriptionSplicing factor 3B subunit 3Homo sapiens (human)
U2-type prespliceosome assemblySplicing factor 3B subunit 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
protein bindingSplicing factor 3B subunit 3Homo sapiens (human)
protein-containing complex bindingSplicing factor 3B subunit 3Homo sapiens (human)
U2 snRNA bindingSplicing factor 3B subunit 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
SAGA complexSplicing factor 3B subunit 3Homo sapiens (human)
nucleusSplicing factor 3B subunit 3Homo sapiens (human)
nucleoplasmSplicing factor 3B subunit 3Homo sapiens (human)
spliceosomal complexSplicing factor 3B subunit 3Homo sapiens (human)
U2-type spliceosomal complexSplicing factor 3B subunit 3Homo sapiens (human)
U2 snRNPSplicing factor 3B subunit 3Homo sapiens (human)
nucleolusSplicing factor 3B subunit 3Homo sapiens (human)
U12-type spliceosomal complexSplicing factor 3B subunit 3Homo sapiens (human)
U2-type precatalytic spliceosomeSplicing factor 3B subunit 3Homo sapiens (human)
catalytic step 2 spliceosomeSplicing factor 3B subunit 3Homo sapiens (human)
nucleusSplicing factor 3B subunit 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1799385WiDr from Article 10.1038/nchembio.2007.16: \\Splicing factor SF3b as a target of the antitumor natural product pladienolide.\\2007Nature chemical biology, Sep, Volume: 3, Issue:9
Splicing factor SF3b as a target of the antitumor natural product pladienolide.
AID1799384VEGF-PLAP from Article 10.1038/nchembio.2007.16: \\Splicing factor SF3b as a target of the antitumor natural product pladienolide.\\2007Nature chemical biology, Sep, Volume: 3, Issue:9
Splicing factor SF3b as a target of the antitumor natural product pladienolide.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (7.14)29.6817
2010's11 (78.57)24.3611
2020's2 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.70 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index5.91 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (14.29%)5.53%
Reviews2 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]